As GLP-1 costs climb, more employers weigh dropping coverage in 2027

Published 4 Min Read

A meticulous Caucasian male examines an Ozempic pen, resembling a modern talisman for World Diabetes Day reflection.
Adobe Stock

  • Key Insight: Learn why employers plan coverage cuts for GLP‑1 drugs in 2027.
  • What’s at Stake: Rising premiums may force employers to redesign benefits and shift cost burdens.
  • Forward Look: Expect stricter utilization controls and program‑based eligibility in employer plans by 2027.
  • Source: Bullets generated by AI with editorial review

A growing number of U.S. employers are expected to drop coverage of GLP-1 drugs in 2027 amid concerns about rising healthcare costs, according to a new survey. 

Jimmy Nesbitt
Reporter

Jimmy Nesbitt is a reporter at Employee Benefit News, where he covers the evolving landscape of workplace benefits, healthcare, retirement, financial wellness and related policy issues. His career … Read full bio


For reprint and licensing requests for this article, click here.


More From Employee Benefit News

Sign Up Form

Login Modal Form